Format

Send to

Choose Destination
Mol Pharm. 2018 Mar 5;15(3):1133-1141. doi: 10.1021/acs.molpharmaceut.7b00996. Epub 2018 Feb 13.

Radiometallic Complexes of DO3A-Benzothiazole Aniline for Nuclear Medicine Theranostics.

Author information

1
Division of RI-Convergence Research , Korea Institute of Radiological and Medical Sciences , Seoul 139-706 , Korea.
2
Division of Medical Radiation Equipment , Korea Institute of Radiological and Medical Sciences , Seoul 139-706 , Korea.

Abstract

To develop a radioactive metal complex platform for tumor theranostics, we introduced three radiopharmaceutical derivatives of 1,4,7,10-tetraazacyclododecane-1,4,7-trisacetic acid-benzothiazole aniline (DO3A-BTA, L1) labeled with medical radioisotopes for diagnosis (68Ga/64Cu) and therapy (177Lu). The tumor-targeting ability of these complexes was demonstrated in a cellular uptake experiment, in which 177Lu-L1 exhibited markedly higher uptake in HeLa cells than the 177Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid complex. According to in vivo positron emission tomography imaging, high accumulation of 68Ga-L1 and 64Cu-L1 was clearly visualized in the tumor site, while 177Lu-L1 showed therapeutic efficacy in therapy experiments. Consequently, this molecular platform represents a useful approach in nuclear medicine toward tumor-theranostic radiopharmaceuticals when 68Ga-L1 or 64Cu-L1 is used for diagnosis, 177Lu-L1 is used for therapy, or two of the compounds are used in conjunction with each other.

KEYWORDS:

177Lu; 64Cu; 68Ga; benzothiazole; radiopharmaceuticals

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center